Capital Research Global Investors
KYMR icon

Capital Research Global Investors’s Kymera Therapeutics KYMR Stock Holding History

Capital Research Global Investors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$139M Buy
1,673,275
+112,484
+7% +$8.91M 0.02% 279
2025
Q4 		$121M Buy
1,560,791
+298,609
+24% +$20.2M 0.02% 282
2025
Q3 		$71.4M Hold
1,262,182
– – 0.01% 322
2025
Q2 		$55.1M Buy
1,262,182
+896,992
+246% +$30.9M 0.01% 338
2025
Q1 		$10M Buy
+365,190
New +$13.3M ﹤0.01% 424

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Capital Research Global Investors's KYMR Position: Q1 2026 in Review

Capital Research Global Investors increased its Kymera Therapeutics (KYMR) stake by 7.2% in Q1 2026, buying an estimated $8.91M and bringing the position to 1,673,275 shares worth $139M. The position accounts for 0.02% of the portfolio, ranked #279.

Capital Research Global Investors first reported a position in KYMR in Q1 2025 and has held it in 5 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Capital Research Global Investors held 1,673,275 shares of Kymera Therapeutics worth $139M as of Q1 2026.
  • Capital Research Global Investors bought 112,484 Kymera Therapeutics shares in Q1 2026, an estimated $8.91M.
  • Kymera Therapeutics made up 0.02% of Capital Research Global Investors's portfolio in Q1 2026, its #279 holding.
  • Capital Research Global Investors first reported a position in Kymera Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Capital Research Global Investors's 13F filing for Q1 2026, filed 13 May 2026.